Similar articles

• Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.

  Stroup JS, Rivers SM, Abu-Baker AM, Kane MP. Stroup JS, et al. Pharmacotherapy. 2007 Jun;27(6):779-88. doi: 10.1592/phco.27.6.779. Pharmacotherapy. 2007. PMID: 17542760 Clinical Trial.
• Teriparatide (forteo) for osteoporsis.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2003 Feb 3;45(1149):9-10. Med Lett Drugs Ther. 2003. PMID: 12571538 Clinical Trial. No abstract available.
• [Treatment of osteoporosis with PTH].

  Takeuchi Y. Takeuchi Y. Clin Calcium. 2014 Jun;24(6):893-902. Clin Calcium. 2014. PMID: 24870841 Review. Japanese.
• Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.

  Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O. Borgström F, et al. J Med Econ. 2010;13(3):381-92. doi: 10.3111/13696998.2010.499072. J Med Econ. 2010. PMID: 20604678
• [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].

  Hashimoto Y, Wakayama N, Miyauchi A. Hashimoto Y, et al. Clin Calcium. 2007 Jan;17(1):48-55. Clin Calcium. 2007. PMID: 17211093 Review. Japanese.